Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma

Sato, Jun; Kimura, Takashi; Saito, Takuro; Anazawa, Takayuki; Kenjo, Akira; Sato, Yoshihiro; Tsuchiya, Takao; Gotoh, Mitsukazu

doi:10.1007/s00534-011-0376-7

Cited by 34 publications

(36 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Under the direct control of Tp53, upregulation of ribonucleo tide reductase p53R2 increases the supply of nucleotides for repairing DNA damage. p53R2 expression is suggested as a predictive marker for resistance to gemcitabine in CCA 304 . Serine/threonine-protein kinase tousled-like kinase 1 is highly expressed in CCA, regulating chromatin assembly and the repair of cisplatin-induced DNA damage 305 .…”

Section: Mechanisms Of Chemoresistancementioning

confidence: 99%

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Bañales

Cardinale

Carpino

et al. 2016

Nat Rev Gastroenterol Hepatol

1,058

1,139

View full text Add to dashboard Cite

Section: Mechanisms Of Chemoresistancementioning

confidence: 99%

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Bañales

Cardinale

Carpino

et al. 2016

Nat Rev Gastroenterol Hepatol

1,058

1,139

View full text Add to dashboard Cite

“…DNA damage induces expression of RRM1 and RRM2b. Overexpression of RNR subunits RRM1 and RRM2a is associated with GEM resistance (11)(12)(13).…”

Section: Gc After the Failure Of Gem For Btcmentioning

confidence: 99%

“…In cholangiocarcinoma, upregulated RNR activity was proposed to influence GEM resistance (13). RNR contains a large subunit [ribonucleotide reductase M1 subunit (RRM1)] and a small subunit [ribonucleotide reductase M2a subunit (RRM2a) and M2b subunit (RRM2b)].…”

Section: Gc After the Failure Of Gem For Btcmentioning

confidence: 99%

A Retrospective Study of Chemotherapy with Cisplatin Plus Gemcitabine After the Failure of Gemcitabine Monotherapy for Biliary Tract Cancer

Kameda¹,

Ando²,

Kobayashi³

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Before the ABC-02 trial, because there was no standard chemotherapy for patients with advanced biliary tract cancer, we treated them with gemcitabine alone. However, recently cisplatin plus gemcitabine became the standard first-line chemotherapy. We assessed the benefits of gemcitabine plus cisplatin chemotherapy after failed gemcitabine monotherapy. Methods: We retrospectively examined patients with advanced biliary tract cancer who were treated with gemcitabine plus cisplatin chemotherapy after failed gemcitabine monotherapy. They had adequate organ function, including renal function and Eastern Cooperative Oncology Group performance status 0 -1. The treatment consisted of cisplatin (25 mg/m 2 of body surface area) plus gemcitabine (1000 mg/m 2 ) on Days 1 and 8 for every 3 weeks. Results: Between December 2010 and January 2013, 20 patients were treated. The median age was 63 years. There were 15 males and 5 females. The ratio of intrahepatic bile duct, gall bladder and extrahepatic bile duct was 9 : 6 : 5. The ratio of locally advanced and metastatic disease was 2 : 18, and the ratio of PS0 and PS1 was 5 : 15. The objective response rate was 15.0%, and the tumour control rate was 60.0%. The median progression-free survival was 6.5 months (95% confidence interval, 2.1 -6.9 months). The median overall survival was 13.7 months (95% confidence interval, 8.3 -19.7 months). Grade 3 -4 toxic events included neutropenia (30%), anaemia (20%) and thrombocytopenia (5%). Conclusion: Cisplatin plus gemcitabine could be an optional therapy for unresectable or recurrent biliary tract cancer after failed gemcitabine monotherapy.

show abstract

“…Gemcitabine is a deoxycytidine analog and is metabolized in tumor cells by deoxycytidine kinase (dCK) to yield active gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). These gemcitabine nucleosides inhibit DNA synthesis in tumor cells 43 . In recent years, gemcitabine and its combination with other anticancer drugs have become popular regimens for the treatment of cholangiocarcinoma 44 .…”

Section: Discussionmentioning

confidence: 99%

The effect of some antineoplastic agents on glutathione S-transferase from human erythrocytes

Erat

Şakiroğlu

2012

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma

Cited by 34 publications

References 18 publications

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

A Retrospective Study of Chemotherapy with Cisplatin Plus Gemcitabine After the Failure of Gemcitabine Monotherapy for Biliary Tract Cancer

The effect of some antineoplastic agents on glutathione S-transferase from human erythrocytes

Contact Info

Product

Resources

About